San Francisco, CA, United States of America

Ellen Filvaroff

This inventor holds 80 USPTO granted patents and 19 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Cancer Treatment (CPC class A61K45-06). Top assignees: Genentech, Inc., Celgene Corporation, Genetech, Inc.. Active years: 2003-2025.

USPTO Granted Patents = 80 (Patent Applications = 19)

% Patents Active = 70.0

CIPO Patents = 4 (Patent Applications = 10)

EPO Patents = 18 (Patent Applications = 22)

Average Co-Inventor Count = 7.1

ph-index = 13

Forward Citations = 660(Granted Patents)

Forward Citations (Not Self Cited) = 617(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Signal Pharmaceuticals, Inc.

patents

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Cancer Treatment

Biomarkers

IL-17 Therapies

Antibody Compositions

Hepatocellular Carcinoma

Vascular Development

Polypeptides

WISP Activity

Humanized Antibodies

Aminoisoindoline Compounds

Combined Use

Monoclonal Antibodies

80 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12474342 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2025-11-18),

2. 12396995 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2025-08-26),

3. 12357633 - Methods of treating cancer by targeting cold tumors (2025-07-15),

4. 11583536 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2023-02-21),

5. 11460471 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2022-10-04),

6. 11096940 - Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection (2021-08-24),

7. 10648983 - Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies (2020-05-12),

8. 10576085 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-03-03),

9. 8790646 - Compositions and methods for modulating vascular development (2014-07-29),

10. 8338132 - Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof (2012-12-25),

11. 8273703 - IL-17 receptor-like polypeptides and therapeutic uses thereof (2012-09-25),

12. 8138152 - Methods of treatment using WISP polypeptides (2012-03-20),

13. 8110548 - Method for treating cartilage disorders (2012-02-07),

14. 8075888 - Methods of treatment using antibodies to IL-17 homologous polypeptides (2011-12-13),

15. 8034342 - Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E (2011-10-11),

Title: Innovator Spotlight: Ellen Filvaroff - Leading the Way in Hematological Malignancy Treatments

Introduction: Ellen Filvaroff, a pioneering inventor based in San Francisco, CA, has made significant contributions to the field of medicine with a focus on treating hematological malignancies. With an impressive portfolio of 77 patents, Filvaroff continues to drive innovation in the healthcare industry.

Latest Patents: Among her latest patents is the groundbreaking invention of Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use. This patent introduces novel methods for treating, preventing, or managing hematological malignancies by combining (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione with a second active agent.

Career Highlights: Ellen Filvaroff has made remarkable contributions during her tenure at renowned companies such as Genentech, Inc. and Celgene Corporation. Her innovative work in pharmaceutical research has revolutionized the treatment landscape for hematological malignancies.

Collaborations: Throughout her career, Filvaroff has collaborated with esteemed professionals in the field, including Audrey Goddard and William I Wood. Together, they have worked towards advancing cancer treatment strategies and utilizing biomarkers to predict clinical sensitivity to therapies.

Conclusion: Ellen Filvaroff's dedication to advancing medical research and developing innovative treatments for hematological malignancies has solidified her position as a trailblazer in the healthcare industry. Her prolific patent portfolio reflects her commitment to making a meaningful impact on patients' lives and reshaping the future of cancer treatment.